A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy

A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy

Item

http://www.wikidata.org/entity/Q24616813

Q24616813

about

Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia.Nutrigenomic Functions of PPARs in Obesogenic Environments.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Saroglitazar for the treatment of dyslipidemia in diabetic patients.Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.Review article: new treatments in non-alcoholic fatty liver disease.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Current and future pharmacologic treatment of nonalcoholic steatohepatitis.The therapeutic landscape of non-alcoholic steatohepatitis.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.Distinct but complementary contributions of PPAR isotypes to energy homeostasis.From 'Make in India' to 'Made in India': the saroglitazar story.PPAR Agonists and Metabolic Syndrome: An Established Role?

P2860

Q24564203-A7C04973-6E2E-496E-95B1-696F0EEF16DD Q33887783-FA180858-B360-4CA6-A278-20F981A54E3D Q34315432-2E85E257-0F8F-45C1-8AE9-E5D28F8EEFF9 Q34469183-ADC180A1-BF1D-4F15-853C-A074FB443100 Q34540703-F59C34DA-8DFB-414B-AF16-D562D0DF12CD Q34877739-6055ACDC-AE7C-4E2F-8320-C8715BF44E01 Q35492306-44F0F148-2417-4A2D-9C2D-1C8C7DBE50A4 Q35822331-65693DD0-2619-4299-9FC5-68FF59DBB9EE Q35899038-2CF76C8B-E6E4-48CD-965D-3A6BD22469CC Q36019949-E0BA6171-A113-4720-B09F-622FE2662D79 Q36831038-9D959F6D-EFDA-4C95-B685-C52A3D20B76D Q37500797-D4FD02A3-E049-4E7F-946A-EBDD7F6431C9 Q38325814-77DCBE28-6F1C-49D4-9224-7193E535AF48 Q38352759-F26C8468-D176-4F53-B13B-735E96C179C4 Q38431166-C01CB79E-EEC8-402F-BE18-0D46091E266F Q38662765-7FF88C7C-F684-4574-86C7-2B2EBF95963C Q38674742-5EAA6A9E-CA1F-4556-AB41-D32F8F04B35B Q38713765-EC746CFD-2382-4CBB-9368-24383BB5BB07 Q38739205-60EA5F3B-3DFB-4D3C-9440-12FD633A20A6 Q38978011-746FEE78-08E2-4102-86B8-6E657EC06361 Q39090639-10414D41-3A05-4966-A16B-D4ED7596C7D1 Q39185669-8A3A28DC-15A4-4272-84B1-C168E872CAC7 Q39214885-2226F11E-27D7-4886-9576-4DA7D59FB15A Q42559674-1F333ECB-A77C-4A82-9093-46E8A3E30643 Q54936265-B243BA5D-AA3C-4FAD-AAA6-33308ADAB191

P2860

A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy

Item

http://www.wikidata.org/entity/Q24616813

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue